BALPHARMA vs BLISSGVS: Stock Comparison

Bal Pharma Limited vs Bliss GVS Pharma Limited

Live data: 22 July 2026, 2:53 PM IST • Source: NSE and company filings

Bliss GVS Pharma Limited is the larger company by market capitalisation. Bal Pharma Limited shows a higher ROE and a higher dividend yield, while Bliss GVS Pharma Limited shows faster revenue growth, lower leverage and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Bal Pharma Limited and Bliss GVS Pharma Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, BALPHARMA is more favourable on 2 of 11 scored metrics and BLISSGVS on 9These counts are context-free and are not an overall rating.

Key Differences

Market Cap
BLISSGVS is the larger company
₹4,782 Cr vs ₹139 Cr
EPS
BLISSGVS has higher earnings per share
₹11.99 vs ₹3.95
Dividend Yield
BALPHARMA has a higher dividend yield
1.32% vs 0.19%
Revenue Growth (TTM YoY)
BLISSGVS has faster revenue growth
29.8% vs 2.7%
EPS Growth (TTM YoY)
BLISSGVS has faster EPS growth
124.7% vs -33.5%
Qtr Sales Growth
BLISSGVS has stronger quarterly sales growth
13% vs 2.69%
Qtr Profit Growth
BLISSGVS has stronger quarterly profit growth
108% vs -33.9%
ROE
BALPHARMA has a higher ROE
7.87% vs 0%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricBALPHARMABLISSGVS
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricBALPHARMABLISSGVS
Live Price₹87.77₹527.1
Day Change-1.67%0.68%
Volume16,9243.93 L
52-Week High₹102.99₹553
52-Week Low₹60₹118
Distance from 52W High-14.78%-4.68%

Valuation

MetricBALPHARMABLISSGVS
Market Cap₹139 Cr₹4,782 Cr
P/E Ratio38.27x
P/B Ratio4.14x
EPS₹3.95₹11.99
Book Value₹51.71₹107.21
Dividend Yield1.32%0.19%

Growth

MetricBALPHARMABLISSGVS
Revenue Growth (TTM YoY)2.7%29.8%
EPS Growth (TTM YoY)-33.5%124.7%
Qtr Sales Growth2.69%13%
Qtr Profit Growth-33.9%108%

Profitability & Leverage

MetricBALPHARMABLISSGVS
ROE7.87%0%
ROCE9.69%11.7%
Net Margin2.02%13.93%
Operating Margin10.2%12.82%
Debt to Equity1.94x1.77x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricBALPHARMABLISSGVS
Promoter Holding46.74%35.36%
FII Holding0.15% 0.01 pp10.45% 4.09 pp
DII Holding0%5.04% 0.74 pp
Public Holding48.99% 0.02 pp49.15% 4.83 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Bal Pharma Limited and Bliss GVS Pharma Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.